Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis. Photo: Handout

Chinese biotech company Ascletis seeks third round of funding that could exceed US$100 million

Hangzhou-based company will consider Hong Kong as potential listing venue when it decides to go public

Topic |   Start-ups

TOP PICKS

Wu Jinzi, founder and chief executive of Hangzhou-based biotechnology company Ascletis. Photo: Handout
READ FULL ARTICLE